{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:46:44Z","timestamp":1774442804210,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.leukres.2024.107545","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T17:30:40Z","timestamp":1718991040000},"page":"107545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML"],"prefix":"10.1016","volume":"143","author":[{"given":"Stephanie","family":"Boisclair","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyu","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Jou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas E.","family":"Gladstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Chitty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.leukres.2024.107545_bib1","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population- based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2024.107545_bib2","first-page":"1249","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"377","author":"Fernandez","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2024.107545_bib3","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2011.606382","article-title":"Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study","volume":"53","author":"Al-Ali","year":"2012","journal-title":"Leuk. Lymphoma"},{"issue":"21","key":"10.1016\/j.leukres.2024.107545_bib4","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"Kantarjian","year":"2012","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.leukres.2024.107545_bib5","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3109\/10428194.2012.762093","article-title":"Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"54","author":"Ritchie","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.leukres.2024.107545_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.leukres.2024.107545_bib7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107545_bib8","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood-2020-134832","article-title":"Cytopenia management in patients with newly diagnosed acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE-a study","volume":"136","author":"Pratz","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.leukres.2024.107545_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.26692","article-title":"Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE-A","volume":"97","author":"Pratz","year":"2022","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.leukres.2024.107545_bib10","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.34608","article-title":"AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed\/refractory patients with acute myeloid leukemia","volume":"129","author":"Todisco","year":"2023","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.leukres.2024.107545_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.leukres.2024.107545_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/oncolo\/oyac135","article-title":"Venetoclax and hypomethylating agents as first-line treatment in newly diagnosed patients with AML in a predominately community setting in the US","volume":"27","author":"Vachhani","year":"2022","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.leukres.2024.107545_bib13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/10428194.2022.2042688","article-title":"Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia","volume":"63","author":"Graveno","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107545_bib14","doi-asserted-by":"crossref","unstructured":"Hoff F.W., Patel P.A., Belli A.J., et al. Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data. https:\/\/doi.org\/101080\/1042819420232197090. 2023;64(6):1123-1128. doi:10.1080\/10428194.2023.2197090.","DOI":"10.1080\/10428194.2023.2197090"},{"issue":"11","key":"10.1016\/j.leukres.2024.107545_bib15","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1007\/s00432-022-03930-5","article-title":"Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia","volume":"148","author":"Fleischmann","year":"2022","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"6","key":"10.1016\/j.leukres.2024.107545_bib16","doi-asserted-by":"crossref","first-page":"7175","DOI":"10.1002\/cam4.5459","article-title":"Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapy","volume":"12","author":"Laloi","year":"2023","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.leukres.2024.107545_bib17","doi-asserted-by":"crossref","DOI":"10.1002\/ccr3.6116","article-title":"Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refractory\/relapsed: a single-centre experience","volume":"10","author":"Rold\u00e1n P\u00e9rez","year":"2022","journal-title":"Clin. Case Rep."},{"issue":"12","key":"10.1016\/j.leukres.2024.107545_bib18","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2024.107545_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00277-023-05102-y","article-title":"Shorter duration of venetoclax administration to 14 days has same efficacy and better safety profile in treatment of acute myeloid leukemia","volume":"102","author":"Aiba","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2024.107545_bib20","doi-asserted-by":"crossref","unstructured":"Karrar O., Abdelmagid M., Rana M., et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol. n\/a(n\/a). doi:10.1002\/ajh.27180.","DOI":"10.1002\/ajh.27180"},{"issue":"1","key":"10.1016\/j.leukres.2024.107545_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2293512","article-title":"Reduced duration and dosage of venetoclax is efficient in newly diagnosed patients with acute myeloid leukemia","volume":"29","author":"Cui","year":"2024","journal-title":"Hematology"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2024.107545_bib22","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/blood-2022-165464","article-title":"Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-na\u00efve patients with acute myeloid leukemia","volume":"140","author":"Willekens","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107545_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bneo.2024.100016","article-title":"Venetoclax and hypomethylating agents in octo- and nonagenarians with acute myeloid leukemia","author":"Madarang","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"3","key":"10.1016\/j.leukres.2024.107545_bib24","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1182\/blood.V91.3.991","article-title":"Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse","volume":"91","author":"Kaufmann","year":"1998","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2024.107545_bib25","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107545_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696532","article-title":"FOXM1-AKT positive regulation loop provides venetoclax resistance in AML","volume":"11","author":"Chesnokov","year":"2021","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.leukres.2024.107545_bib27","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.2021013788","article-title":"A BAX door to venetoclax resistance","volume":"139","author":"Izzo","year":"2022","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624001115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T23:46:24Z","timestamp":1722987984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624001115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":27,"alternative-id":["S0145212624001115"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107545","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Less is more: An analysis of venetoclax and hypomethylating agent post-induction treatment modifications in AML","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107545"}}